Ras association domain family 1A (RASSF1A) is a tumour suppressor and regulates cell cycle, apoptosis and microtubule stability.
This is the first study to identify associations between RASSF1A polymorphisms and clinicopathological parameters and survival in patients with clear cell renal cell carcinoma (CCRCC). RASSF1A genotyping may be useful for predicting the prognosis of the clinical course of CCRCC, and this finding might provide a better understanding of the mechanism underlying the development and progression of CCRCC. However, functional and prospective studies with a larger number of patients are needed to confirm the results.
OBJECTIVE:To compare Ras association domain family 1A (RASSF1A) genotypes or haplotypes with clinicopathological characteristics and survival rates of patients with clear cell renal cell carcinoma (CCRCC).
PATIENTS AND METHODS:The study cohort comprised 224 Japanese patients who underwent radical nephrectomy and had CCRCC confirmed by histopathological analysis. Three common polymorphisms in the RASSF1A gene, 133Ala/Ser (G/T), -710C/T and -392C/T, were genotyped using TaqMan assays and haplotypes were analysed using appropriate software.
RESULTS:Patients with CCRCC with RASSF1A -710TT genotype exhibited a significantly higher tumour stage and higher stage grouping than those with -710CC or -710CT (P = 0.005 and P = 0.032, respectively). There was no significant association between 133Ala/Ser or -392C/T genotype and clinicopathological characteristics. RASSF1A 133Ala-710T-392T haplotype and -710TT genotype were significantly associated with poorer recurrence-free survival rates (P = 0.038 and P = 0.007, respectively).
CONCLUSIONS: This is the first study to identify associations between RASSF1A polymorphisms and clinicopathological parameters and survival in patients with CCRCC. RASSF1A genotyping may be useful in predicting the prognosis of the clinical course of CCRCC, and this finding might provide a better understanding of the mechanism underlying the development and progression of CCRCC. Functional and prospective studies with a larger number of patients are needed to confirm the results.
Written by:
Kawai Y, Sakano S, Okayama N, Suehiro Y, Matsuyama H, Hinoda Y. Are you the author?
Departments of Urology and Laboratory Medicine, Graduate School of Medicine, Yamaguchi University, Ube, Japan.
Reference: BJU Int. 2012 Apr 23. Epub ahead of print.
doi: 10.1111/j.1464-410X.2012.11143.x
PubMed Abstract
PMID: 22520501
UroToday.com Renal Cancer Section
